Loading…
Live market data via Yahoo Finance · updated 8/1/2026
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates.
The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets.
It was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California. As of July 14, 2026, XOMA Royalty Corporation operates as a subsidiary of Ligand Pharmaceuticals Incorporated.
XOMA Royalty Corporation (XOMA) is currently priced at $40.17 and is listed with a market cap of $710.16M, ranking 2795. The stock currently trades in a market position typical of a niche biotech royalty company within the healthcare sector.
The price outlook from the provided forecasts shows a bullish long‑term path, with the 2026 average at $40.17 and substantial upside expected in later years. The forecasted averages rise to $62.29 in 2027, $79.54 in 2028, and $96.31 in 2029, continuing to higher levels through 2030 ($105.69), 2040 ($412.34), and 2050 ($1,005.80).
Implied returns grow over time, with ROI reaching 55.1% in 2027, 98% in 2028, 139.8% in 2029, 163.1% in 2030, 926.5% in 2040, and 2403.9% in 2050, reflecting a strong longer‑term trajectory despite near‑term variability.
A major floor 34.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 16.0% above — clearing it would confirm fresh momentum.
Key XOMA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of XOMA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $40.17 | Buy | $40.41 | Sell |
| MA 10 | $41.52 | Sell | $41.03 | Sell |
| MA 20 | $42.08 | Sell | $41.57 | Sell |
| MA 50 | $41.92 | Sell | $40.97 | Sell |
| MA 100 | $37.70 | Buy | $38.47 | Buy |
| MA 200 | $33.78 | Buy | $35.19 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.34 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -94.30 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.41 | Sell |
| ROC (12) | -6.58 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.01 | Sell |
| Awesome (5,34) | -1.83 | Sell |
| Ultimate (7,14,28) | 15.47 | Buy |
| Momentum (10) | -3.72 | Sell |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 39.67 | Buy |
| ADX (14) | 35.50 | Sell |
| ATR (14) | 0.36 | Info |
In the near term, sentiment is shown as BULLISH with a current RSI of 70. The 50‑day simple moving average is $42.07, above the 200‑day simple moving average of $33.69, indicating constructive momentum.
Key support and resistance are listed at $41.69 and $45.00 respectively, framing a narrow near‑term range alongside the thirty‑day range of $37.01 to $43.60. These indicators suggest a bullish tilt within a tight band over the next month.
See what a past investment in XOMAwould be worth at today's price.
$1,000 invested in XOMA on Jul 21, 2025 (≈ 39.246469 XOMA) would be worth
$1,576.53
+$576.53 (+57.7%) today · 1.58× · US Dollar
Based on a XOMA entry price of $25.48 vs. today's $40.17.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $40.17 | $1,000 | +0.0% |
| 1 month ago | $42 | $956.43 | -4.4% |
| 3 months ago | $39.37 | $1,020.32 | +2.0% |
| 6 months ago | $26.92 | $1,492.2 | +49.2% |
| 1 year ago | $25.48 | $1,576.53 | +57.7% |
| All time (5.0y) ago | $32.45 | $1,237.9 | +23.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
The multi‑year forecast depicts a sustained bullish trajectory with rising average prices and meaningful upside across the horizon. The 2026 forecast shows an average of $40.17 with a neutral sentiment, while 2027–2050 projects progressively higher averages and strong ROIs.
Notably, the 2030 average is $105.69 with a 163.1% ROI, the 2040 average is $412.34 with a 926.5% ROI, and the 2050 average is $1,005.80 with a 2403.9% ROI. The max values for these years also reflect substantial upside, reaching $144.05 in 2030, $628.91 in 2040, and $1,644.45 in 2050. The overall sentiment remains BULLISH across 2027 through 2050, indicating a strong longer‑term growth outlook.
Tap a question to reveal the answer.
The forecast for 2030 shows an avg of $105.69 with a min of $82.57 and a max of $144.05, and a ROI of 163.1% with a bullish sentiment.
The forecast indicates a bullish sentiment from 2027 onward with rising averages and high ROIs (e.g., 2027 avg $62.29, ROI 55.1%; 2040 avg $412.34, ROI 926.5%; 2050 avg $1,005.80, ROI 2403.9%), though 2026 shows a neutral outlook.
Yes. The 2050 forecast lists an average price of $1,005.80 with a max of $1,644.45 and an ROI of 2403.9%, indicating substantial upside in the long term.
The current price is $40.17 and the market cap is $710.16M, with a rank of 2795.
The near‑term technical picture is bullish, with RSI14 at 70, a 50‑day SMA of $42.07, a 200‑day SMA of $33.69, a support at $41.69, a resistance at $45.00, and a 30‑day range of $37.01 to $43.60.
XOMA Royalty Corp Community Discussion
0Share your XOMA Royalty Corp price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.